Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20250101 - 20251231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 25491822 |
US |
30 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 2 | 25494656 |
US |
56 | 2 |
Exposure via skin contact, Injection site haemorrhage, Wrong technique in device usage process, Accidental exposure to product, Incorrect dose administered, |
||||
BELIMUMAB, |
||||
| 3 | 25495556 |
US |
1 | |
Occupational exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 4 | 25495566 |
US |
83 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 5 | 25495598 |
US |
58 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 6 | 25495703 |
US |
50 | 2 |
Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 7 | 25495704 |
US |
61 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 8 | 25495708 |
US |
76 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 9 | 25495727 |
US |
70 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 10 | 25495784 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 11 | 25495787 |
US |
82 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 12 | 25495796 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 13 | 25495834 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, |
||||
| 14 | 25495840 |
US |
72 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 15 | 25496060 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 16 | 25490969 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 17 | 25491071 |
US |
64 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 18 | 25491227 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 19 | 25491369 |
US |
60 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, |
||||
| 20 | 25491489 |
US |
13 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 21 | 25489953 |
US |
61 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 22 | 25490022 |
US |
54 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 23 | 25490273 |
US |
27 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 24 | 25490274 |
US |
76 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 25 | 25490280 |
US |
17 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 26 | 25490287 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 27 | 25490361 |
US |
52 | 2 |
Rash, Underdose, Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 28 | 25490371 |
US |
64 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 29 | 25486442 |
US |
61 | 2 |
Ocular discomfort, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 30 | 25489128 |
US |
13 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 31 | 25489135 |
US |
74 | 1 |
Hypoacusis, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 32 | 25489137 |
US |
81 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 33 | 25489179 |
US |
14 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 34 | 25489192 |
US |
76 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 35 | 25489220 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 36 | 25489368 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 37 | 25489384 |
US |
71 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 38 | 25489390 |
US |
70 | 1 |
Product dispensing error, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 39 | 25489475 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 40 | 25489481 |
US |
46 | 1 |
Accidental exposure to product, Exposure via skin contact, Off label use, |
||||
INSULIN GLARGINE, |
||||
| 41 | 25489497 |
US |
7 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 42 | 25490504 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 43 | 25490570 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 44 | 25490781 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 45 | 25490804 |
US |
67 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 46 | 25490829 |
US |
9 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 47 | 25481256 |
US |
2 | |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Underdose, Product complaint, |
||||
BELIMUMAB, |
||||
| 48 | 25481681 |
US |
70 | 1 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 49 | 25483629 |
DE |
1 | |
Device malfunction, Exposure via skin contact, |
||||
ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, |
||||
| 50 | 25484118 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 51 | 25484238 |
US |
19 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 52 | 25484297 |
US |
13 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 53 | 25484357 |
US |
65 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 54 | 25484373 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 55 | 25484382 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 56 | 25484415 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 57 | 25484426 |
US |
69 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 58 | 25484429 |
US |
26 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 59 | 25484770 |
US |
47 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 60 | 25486249 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 61 | 25486317 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, OCTOCRYLENE, AVOBENZONE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, MOMETASONE FUROATE, MOMETASONE, |
||||
| 62 | 25475939 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 63 | 25477111 |
US |
32 | 2 |
Cardiac failure, Exposure via skin contact, Drug hypersensitivity, Accidental underdose, Device defective, |
||||
OMALIZUMAB, OMALIZUMAB, FUROSEMIDE, |
||||
| 64 | 25479451 |
US |
6 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 65 | 25479465 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 66 | 25479557 |
US |
40 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 67 | 25479587 |
US |
26 | 1 |
Accidental exposure to product, Exposure via skin contact, Wrong technique in product usage process, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 68 | 25479590 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 69 | 25479685 |
US |
47 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 70 | 25479735 |
US |
85 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 71 | 25479767 |
US |
61 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 72 | 25480215 |
US |
14 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 73 | 25470446 |
US |
2 | |
Injection site bruising, Accidental exposure to product, Exposure via skin contact, Wrong technique in device usage process, Device leakage, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 74 | 25470564 |
US |
2 | |
Injection site pain, Injection site discolouration, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, Wrong technique in device usage process, Device mechanical issue, Device mechanical issue, |
||||
SOMATROPIN, SOMATROPIN, SOMATROPIN, SOMATROPIN, |
||||
| 75 | 25470696 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 76 | 25470893 |
US |
61 | 2 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 77 | 25471780 |
CA |
1 | 2 |
Feeling hot, Pneumonia, Exposure via skin contact, Accidental exposure to product, |
||||
SOMATROPIN, |
||||
| 78 | 25473778 |
CH |
||
Device malfunction, Needle issue, Off label use, Exposure via skin contact, Inappropriate schedule of product administration, |
||||
ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, LEVOTHYROXINE SODIUM, FOLLITROPIN ALFA, NILOTINIB, |
||||
| 79 | 25474549 |
US |
49 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, INSULIN GLARGINE, |
||||
| 80 | 25474565 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 81 | 25474610 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 82 | 25474644 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 83 | 25474708 |
US |
49 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 84 | 25474829 |
US |
58 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 85 | 25474881 |
US |
66 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 86 | 25474912 |
US |
77 | 1 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 87 | 25474917 |
US |
65 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 88 | 25474933 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 89 | 25474942 |
US |
34 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 90 | 25475689 |
US |
78 | 2 |
Eye irritation, Product dose omission in error, Accidental exposure to product, Product use complaint, Exposure via skin contact, Patient dissatisfaction with treatment, Product container issue, |
||||
PERFLUOROHEXYLOCTANE, |
||||
| 91 | 25468137 |
US |
||
Drug dose omission by device, Accidental exposure to product, Device leakage, Exposure via skin contact, Device delivery system issue, |
||||
| 92 | 25468525 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 93 | 25468548 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 94 | 25468585 |
US |
64 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 95 | 25468593 |
US |
28 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 96 | 25468640 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 97 | 25468648 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 98 | 25468656 |
US |
80 | 2 |
Injection site reaction, Device operational issue, Accidental exposure to product, Exposure via skin contact, Product prescribing issue, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 99 | 25468754 |
US |
59 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 100 | 25468800 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-07-29